Scientists from Duke-NUS Medical School (Duke-NUS) have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a (1). This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain --- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.

The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature.

In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company's experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.

The treatment was originally intended to demonstrate the safety of the latest generation of the therapies. But if early data is accurate, it is already the world's first successful example of telomere lengthening via gene therapy in a human individual. Gene therapy has been used to lengthen telomeres before in cultured cells and in mice, but never in a human patient.

CORVALLIS, Ore. - The soaring canopy and dense understory of an old-growth forest could provide a buffer for plants and animals in a warming world, according to a study from Oregon State University published today in Science Advances.

Comparing temperature regimes under the canopy in old-growth and plantation forests in the Oregon Cascades, researchers found that the characteristics of old growth reduce maximum spring and summer air temperatures as much as 2.5 degrees Celsius (4.5 degrees Fahrenheit), compared to those recorded in younger second-growth forests.

Landowners who include biodiversity as a management goal, the scientists said, could advance their aims by fostering stands with closed canopies, high biomass and complex understory vegetation.

A team of researchers at Sinai Health System's Lunenfeld-Tanenbaum Research Institute (LTRI) and University of Toronto's Donnelly Centre has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions. The paper will be published today in the journal Molecular Systems Biology.

The smoking cessation aids varenicline (Chantix) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events compared to the nicotine patch and a placebo, according to data published in The Lancet.

After reports claiming varenicline and bupropion might cause adverse neuropsychiatric events, such as increased agitation, depression, hostility or suicidal behavior, the
Food and Drug Administration (FDA) requested that both medications carry boxed warnings in their labeling, which resulted in limitation in use and thus fewer ways to quit.